자동 주사기 시장 규모, 점유율, 동향 분석 : 제품별, 적응증별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Autoinjectors Market Growth & Trends:

The global autoinjectors market size is expected to reach USD 20.6 billion by 2030, registering a CAGR of 15.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising incidence of anaphylactic shock and other diseases such as diabetes, rheumatoid, & multiple sclerosis along with increasing approvals of auto-injectors are impelling growth.

Increasing prevalence of life-threatening allergies and rising demand for these devices are expected to aid growth. As per the Food Allergy Research & Education, around 200, 000 people every year need emergency medical care for allergic food reactions.

In addition, increasing approvals are anticipated to drive growth. For instance, in August 2018, U.S. FDA approved the first generic epinephrine auto-injector of Teva Pharmaceuticals to treat emergency allergic reactions, including anaphylaxis. Generic versions of EpiPen Jr & EpiPen of 0.15 mg & 0.3 mg, respectively, are indicated for pediatric and adult patients weighing more than 33 pounds.

Moreover, manufacturers are also developing new products and innovative technologies, which is expected to propel market growth. For instance, in June 2018, AbbVie GK launched Humira, which is a fully human antitumor necrosis factor alpha monoclonal antibody formulation with lock function & injection start & end alerts as well as an inspection window and injects completely in 10 seconds. Demand for these devices is increasing as they are designed in accordance with patient acceptance and compliance. Technological advancements are anticipated to make them more convenient and user-friendly. This is encouraging patients to adopt this technology for chronic illnesses.

Autoinjectors Market Report Highlights:

• The disposable autoinjectors segment accounted for the largest market share of 56.8% in 2024 and is expected to witness the fastest CAGR over the forecast period. The reusable auto injector segment is witnessing significant growth, driven by increasing patient preference for convenience and cost-effectiveness.
• The diabetes segment accounted for the largest market share of 28.9% in 2024. The multiple sclerosis (MS) segment is expected to witness the fastest growth over the forecast period.
• The homecare settings segment accounted for the largest revenue share of 54.1% in 2024 and is expected to witness the fastest growth over the forecast period. The hospitals and clinics segment is also expected to witness significant growth over the forecast period.
• The North America autoinjectors market dominated the overall global market and accounted for the 45.3% revenue share in 2024. The autoinjectors market in the U.S. held a significant share of North America's auto-injectors industry in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.1. Segment Definitions
  • 1.1.1. Product
  • 1.1.2. Indication
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecasts timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Indication outlook
  • 2.2.3. End Use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Auto-Injectors Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing prevalence of targeted therapies
    • 3.2.1.2. Increase in the incidence of anaphylactic shock
    • 3.2.1.3. Patients' preference to choose self-administration of injections
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Availability of its substitute products like general injections and oral tablets
• 3.3. Auto-Injectors Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Auto-Injectors Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Auto-Injectors Market: Product Movement Analysis
• 4.3. Auto-Injectors Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Disposable Auto-Injectors
  • 4.5.1. Disposable Auto-Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Reusable Auto-Injectors
  • 4.6.1. Reusable Auto-Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.1.1. Prefilled Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.6.1.1.1. Prefilled Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.1.2. Empty Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.6.1.2.1. Empty Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Auto-Injectors Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Auto-Injectors Market: Indication Movement Analysis
• 5.3. Auto-Injectors Market by Indication Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Rheumatoid Arthritis
  • 5.5.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Multiple Sclerosis
  • 5.6.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Diabetes
  • 5.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Anaphylaxis
  • 5.8.1. Anaphylaxis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Other Therapies
  • 5.9.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Auto-Injectors Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Auto-Injectors Market: End Use Movement Analysis
• 6.3. Auto-Injectors Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Homecare Settings
  • 6.5.1. Homecare Settings Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Hospitals & Clinics
  • 6.6.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Ambulatory Surgical Centers
  • 6.7.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Auto-Injectors Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Auto-Injectors Market movement analysis
• 7.3. Auto-Injectors Market: Regional Estimates & Trend Analysis by Product, Indication & End Use
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. North America
  • 7.5.1. North America Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait Auto-Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Share Analysis, 2024
• 8.3. Key Company Profiles
  • 8.3.1. Eli Lilly
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. SHL Medical AG
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. AbbVie, Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Amgen
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Owen Mumford
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Ypsomed
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Teva Pharmaceutical
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Biogen Idec
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Mylan N.V.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Pfizer, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Sanofi
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Gerresheimer AG
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives